TRAF2 (4C4) Monoclonal Antibody

$Lane 1: 293; Lane 2: Hela whole cell lysate at 20 \u00b5g per lane, probed with TRAF2 (214CT16.3.4) Monoclonal Antibody, unconjugated (bsm-51060M) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.$

Lane 1: 293; Lane 2: Hela whole cell lysate at 20 \u00b5g per lane, probed with TRAF2 (214CT16.3.4) Monoclonal Antibody, unconjugated (bsm-51060M) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.

Applications

Reactivity

Human

Overview
Catalog #	bsm-51060M
Product Name	TRAF2 (4C4) Monoclonal Antibody
Applications	WB, IF
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Mouse
Source	This TRAF2 monoclonal antibody is generated from mouse immunized with TRAF2 recombinant protein.
Clonality	Monoclonal
Clone #	4C4
Isotype	IgG1
Concentration	0.5ug/ul
Purification	Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Store at -20°C for 12 months.
Target
Gene ID	7186
Swiss Prot	Q12933
Synonyms	TRAP; TRAP3; MGC:45012; TNF receptor-associated factor 2; E3 ubiquitin-protein ligase TRAF2; Tumor necrosis factor type 2 receptor-associated protein 3; TRAF2
Background	Regulates activation of NF-kappa-B and JNK and plays a central role in the regulation of cell survival and apoptosis. Required for normal antibody isotype switching from IgM to IgG. Has E3 ubiquitin-protein ligase activity and promotes 'Lys-63'-linked ubiquitination of target proteins, such as BIRC3, RIPK1 and TICAM1. Is an essential constituent of several E3 ubiquitin-protein ligase complexes, where it promotes the ubiquitination of target proteins by bringing them into contact with other E3 ubiquitin ligases. Regulates BIRC2 and BIRC3 protein levels by inhibiting their autoubiquitination and subsequent degradation; this does not depend on the TRAF2 RING-type zinc finger domain. Plays a role in mediating activation of NF-kappa-B by EIF2AK2/PKR. In complex with BIRC2 or BIRC3, promotes ubiquitination of IKBKE.
Application Dilution
WB	1:300-5000
IF